Actinium (225Ac) rhPSMA-10.1
Phase 2Radiopharmaceutical
Actinium (225Ac) rhPSMA-10.1 is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Radium-223
BayerPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity College, London